Chairman of Scientific Advisory Board
Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx.
He was a co-founder of Medco Research Inc., a NYSE listed clinical research organization and biotechnology company specializing in adenosine products that was subsequently acquired by King Pharmaceuticals. Dr. Hausman was also a co-founder of Axonyx, and served in various capacities as President, CEO and Chairman until the company merged into NASDAQ listed Torrey Pines Therapeutics Inc. in 2006. Dr. Hausman is currently a Director of NuGenerex Biotechnology Corporation and is Chairman of the Board of Directors and Chief Science and Technology Officer of Entia Biosciences Inc.
Dr. Hausman has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in Urological Surgery at UCLA Medical Center. He received his medical degree from New York University School of Medicine.
He is on the Alumni Board of Governors of NYU Grossman School of Medicine.
Preclinical ASD Study Liaison
Dr. Ambert is currently Director of Data Science at Nike, Inc. and has extensive experience in data analytics, machine learning, artificial intelligence and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.
Lead Scientist, Strategic Advisor
Specializing in scientific discovery and corporate strategy, Dr. Perederiy holds expertise along the full spectrum of biological innovation, from single-cell analytics to systems-level therapeutics. Julia is an author of multiple peer-reviewed publications, including highly regarded studies on the neurogenetics of autism and brain plasticity in neurodegeneration.
Dr. Perederiy is also an experienced entrepreneur and management consultant, helping biotechnology companies with business planning, market research and fundraising. Dr. Perederiy holds Bachelor’s degrees in Neurobiology and Psychology from the University of California, Berkeley, a Master’s in Technology Entrepreneurship from University of Portland and a PhD in Neuroscience from Oregon Health & Science University.
Gary R. Harlem is the founder and CEO of Altucell Biotech, a cellular engineering and biotech company focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of diabetes and other autoimmune and neurodegenerative diseases. He is an accomplished entrepreneur focused on the health and wellness sector, launching several companies in the nutritional supplement and health food markets.
Mr. Harlem has a degree in Education from Dowling College in New York and began his career as a special education teacher. He became interested in exploring novel treatment strategies for autoimmune diseases when his son was diagnosed with Type 1 diabetes at the age of 10.